drugset / Trial / NCT00120250

Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder

NCT00120250

Phase 4 Completed 27 enrolled Massachusetts General Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.

Timeline

Start
2005-06
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg